Lymphoma Clinical Trial
Official title:
Treatment of Children With Cancer
This protocol is designed to evaluate children with cancer who appear to be probable candidates for future protocol entry or have disease manifestations that are of unique scientific importance or educational value.
Background:
Children and adults are referred to the Pediatric Oncology Branch (POB) for possible
enrollment in clinical protocols for the treatment of cancer or other rare diseases. While
some children are not eligible for a specific protocol, they may present with disease
manifestations that offer the potential for important new insights into the pathogenesis or
clinical behavior of their underlying disease. In addition, children who have completed
participation in a clinical protocol but do not currently have therapeutic protocol
alternatives may continue to provide POB with important information. Diseases of interest to
the POB include, but are not limited to lymphoma, brain tumors, Ewing's sarcoma, leukemia,
neuroectodermal tumors, osteosarcoma, rhabdomyosarcoma, RAS-related syndromes and inherited
immune disorders, amongst others. Hence, serial clinical evaluation of such patients,
including the performance of clinical, laboratory, and diagnostic studies to help elucidate
longitudinally the underlying disease mechanisms, and when clinically indicated standard care
therapies, will assist POB meet its overall mission.
Objectives:
To be able to follow and evaluate children and adults with cancer or pre-cancer syndromes and
other rare diseases referred to the Pediatric Oncology Branch who present with disease
manifestations that lend themselves to clinical evaluation and are of unique scientific
importance.
Eligibility:
Patients who are evaluated by the Pediatric Oncology Branch and are:
- Children and adults with cancer (or a pre-cancer syndrome or rare disease), with disease
manifestations of special interest to Pediatric Oncology Branch investigators.
- Patients must be greater than or equal to 2 years and less than or equal to 40 years of
age at the time of study enrollment.
Design:
The medical procedures or tests will be selected for each patient on the basis of his/her
individual diagnosis (or presumed diagnosis). When clinically indicated, standard therapy
will be administered and patients will be followed according to standard medical practice.
Specimens may be collected for clinical care purposes only to evaluate the patient s status.
No investigational tests, drugs or therapies will be administered in this protocol.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |